VPA does not enhance platinum binding to DNA in cisplatin-resistant neuroblastoma cancer cells

Neuroblastoma represents a malignancy of the sympathetic nervous system characteristic by biological heterogeneity. Thus, chemotherapy exhibits only low effectivity in curing high-risk forms. Previous studies revealed the cytotoxic potential of valproate on neuroblastoma cells. Nevertheless, these s...

Full description

Saved in:
Bibliographic Details
Main Authors: Martina Raudenska, Ludmila Krejcova, Lukas Richtera, Zbynek Heger, Jan Hrabeta, Tomas Eckschlager, Marie Stiborova, Vojtech Adam, Monika Kratochvilova, Michal Masarik, Jaromir Gumulec
Format: Article
Language:English
Published: SAGE Publishing 2017-09-01
Series:Tumor Biology
Online Access:https://doi.org/10.1177/1010428317711656
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849398352602464256
author Martina Raudenska
Ludmila Krejcova
Lukas Richtera
Zbynek Heger
Jan Hrabeta
Tomas Eckschlager
Marie Stiborova
Vojtech Adam
Monika Kratochvilova
Michal Masarik
Jaromir Gumulec
author_facet Martina Raudenska
Ludmila Krejcova
Lukas Richtera
Zbynek Heger
Jan Hrabeta
Tomas Eckschlager
Marie Stiborova
Vojtech Adam
Monika Kratochvilova
Michal Masarik
Jaromir Gumulec
author_sort Martina Raudenska
collection DOAJ
description Neuroblastoma represents a malignancy of the sympathetic nervous system characteristic by biological heterogeneity. Thus, chemotherapy exhibits only low effectivity in curing high-risk forms. Previous studies revealed the cytotoxic potential of valproate on neuroblastoma cells. Nevertheless, these studies omitted effects of hypoxia, despite its undeniable tumorigenic role. In this study, we addressed the question whether valproate promotes binding of platinum-based anti-cancer drugs (cisplatin, carboplatin and oxaliplatin) to DNA and role of hypoxia, cellular antioxidant capacity and cisplatin resistance in this process. Following parameters differed significantly when cells were exposed to treatment with platinum-based drugs: elevation of platinum content bound to DNA, elevation of total thiol content, GSH/GSSG ratio, glutathione reductase and peroxidase, superoxide dismutase and elevation of antioxidant capacity. Hypoxia caused a decrease in cytosine/adenine peak, and no changes in platinum–DNA binding properties were observed. After valproate co-treatment, oxidative stress–related parameters and cytosine/adenine peak were only elevated. The amount of platinum bound to DNA was not changed significantly. Valproate is not able to enhance platinum binding to DNA in neuroblastoma cells, neither in case of intrinsic resistance (UKF-NB-4) nor in case of acquired resistance (UKF-NB-4 CDDP ). Therefore, another mechanism different from increase in platinum binding to DNA should be considered as a synergistic effect of valproate by cisplatin treatment.
format Article
id doaj-art-b0971fb99a644becbfca7f7df620ebb9
institution Kabale University
issn 1423-0380
language English
publishDate 2017-09-01
publisher SAGE Publishing
record_format Article
series Tumor Biology
spelling doaj-art-b0971fb99a644becbfca7f7df620ebb92025-08-20T03:38:38ZengSAGE PublishingTumor Biology1423-03802017-09-013910.1177/1010428317711656VPA does not enhance platinum binding to DNA in cisplatin-resistant neuroblastoma cancer cellsMartina Raudenska0Ludmila Krejcova1Lukas Richtera2Zbynek Heger3Jan Hrabeta4Tomas Eckschlager5Marie Stiborova6Vojtech Adam7Monika Kratochvilova8Michal Masarik9Jaromir Gumulec10Central European Institute of Technology, Brno University of Technology, Brno, Czech RepublicDepartment of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech RepublicDepartment of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech RepublicDepartment of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech RepublicDepartment of Paediatric Haematology and Oncology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech RepublicDepartment of Paediatric Haematology and Oncology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech RepublicDepartment of Biochemistry, Faculty of Science, Charles University, Prague, Czech RepublicDepartment of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech RepublicCentral European Institute of Technology, Brno University of Technology, Brno, Czech RepublicCentral European Institute of Technology, Brno University of Technology, Brno, Czech RepublicCentral European Institute of Technology, Brno University of Technology, Brno, Czech RepublicNeuroblastoma represents a malignancy of the sympathetic nervous system characteristic by biological heterogeneity. Thus, chemotherapy exhibits only low effectivity in curing high-risk forms. Previous studies revealed the cytotoxic potential of valproate on neuroblastoma cells. Nevertheless, these studies omitted effects of hypoxia, despite its undeniable tumorigenic role. In this study, we addressed the question whether valproate promotes binding of platinum-based anti-cancer drugs (cisplatin, carboplatin and oxaliplatin) to DNA and role of hypoxia, cellular antioxidant capacity and cisplatin resistance in this process. Following parameters differed significantly when cells were exposed to treatment with platinum-based drugs: elevation of platinum content bound to DNA, elevation of total thiol content, GSH/GSSG ratio, glutathione reductase and peroxidase, superoxide dismutase and elevation of antioxidant capacity. Hypoxia caused a decrease in cytosine/adenine peak, and no changes in platinum–DNA binding properties were observed. After valproate co-treatment, oxidative stress–related parameters and cytosine/adenine peak were only elevated. The amount of platinum bound to DNA was not changed significantly. Valproate is not able to enhance platinum binding to DNA in neuroblastoma cells, neither in case of intrinsic resistance (UKF-NB-4) nor in case of acquired resistance (UKF-NB-4 CDDP ). Therefore, another mechanism different from increase in platinum binding to DNA should be considered as a synergistic effect of valproate by cisplatin treatment.https://doi.org/10.1177/1010428317711656
spellingShingle Martina Raudenska
Ludmila Krejcova
Lukas Richtera
Zbynek Heger
Jan Hrabeta
Tomas Eckschlager
Marie Stiborova
Vojtech Adam
Monika Kratochvilova
Michal Masarik
Jaromir Gumulec
VPA does not enhance platinum binding to DNA in cisplatin-resistant neuroblastoma cancer cells
Tumor Biology
title VPA does not enhance platinum binding to DNA in cisplatin-resistant neuroblastoma cancer cells
title_full VPA does not enhance platinum binding to DNA in cisplatin-resistant neuroblastoma cancer cells
title_fullStr VPA does not enhance platinum binding to DNA in cisplatin-resistant neuroblastoma cancer cells
title_full_unstemmed VPA does not enhance platinum binding to DNA in cisplatin-resistant neuroblastoma cancer cells
title_short VPA does not enhance platinum binding to DNA in cisplatin-resistant neuroblastoma cancer cells
title_sort vpa does not enhance platinum binding to dna in cisplatin resistant neuroblastoma cancer cells
url https://doi.org/10.1177/1010428317711656
work_keys_str_mv AT martinaraudenska vpadoesnotenhanceplatinumbindingtodnaincisplatinresistantneuroblastomacancercells
AT ludmilakrejcova vpadoesnotenhanceplatinumbindingtodnaincisplatinresistantneuroblastomacancercells
AT lukasrichtera vpadoesnotenhanceplatinumbindingtodnaincisplatinresistantneuroblastomacancercells
AT zbynekheger vpadoesnotenhanceplatinumbindingtodnaincisplatinresistantneuroblastomacancercells
AT janhrabeta vpadoesnotenhanceplatinumbindingtodnaincisplatinresistantneuroblastomacancercells
AT tomaseckschlager vpadoesnotenhanceplatinumbindingtodnaincisplatinresistantneuroblastomacancercells
AT mariestiborova vpadoesnotenhanceplatinumbindingtodnaincisplatinresistantneuroblastomacancercells
AT vojtechadam vpadoesnotenhanceplatinumbindingtodnaincisplatinresistantneuroblastomacancercells
AT monikakratochvilova vpadoesnotenhanceplatinumbindingtodnaincisplatinresistantneuroblastomacancercells
AT michalmasarik vpadoesnotenhanceplatinumbindingtodnaincisplatinresistantneuroblastomacancercells
AT jaromirgumulec vpadoesnotenhanceplatinumbindingtodnaincisplatinresistantneuroblastomacancercells